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Key Clinical Message
Hereditary spastic paraplegia is a group of clinically and genetically heteroge-
neous neurodegenerative disorders, often characterized by weakness and spastic-
ity in the lower limbs. In our study, we describe a spastic paraplegia type 7
patient with an expanded phenotype who was diagnosed after the discovery of
pathogenic variants in SPG7.
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Introduction
Hereditary spastic paraplegia (HSP) is a group of neurode-
generative disorders characterized by progressive bilateral
lower limb weakness and spasticity. In addition, HSP
patients may also develop hyperreflexia in the arms, dys-
phagia, ataxia, nystagmus and strabismus, loss of hearing,
motor and sensory neuropathy, and amyotrophy [1].
According to OMIM, over 80 different genetic loci have
been identified to cause HSP through autosomal dominant,
autosomal recessive, or X-linked modes of inheritance
(https://omim.org/) [2, 3]. Proteins encoded by these genes
have a wide range of functions, including myelin forma-
tion, axonal transport, endoplasmic reticulum morphology,
and mitochondrial function [2]. The most common patho-
logical feature of HSP is selective degeneration of the corti-
cospinal tract and fasciculus gracilis, suggesting that these
proteins are somehow involved in the survival of specific
neurons [4]. Postmortem studies have also concluded that
in some cases, degeneration may extend into the midbr-
ain to include the pons, medulla, cerebral peduncles, or
beyond [2].
Spastic paraplegia type 7 (SPG7, MIM: 607259) is an
autosomal recessive HSP caused by various pathogenic
variants (i.e., missense, nonsense, splice site, frameshift,
and deletion or duplication) in the spastic paraplegia 7
gene (SPG7, MIM: 602783) [1, 5, 6]. SPG7 encodes for
paraplegin, a nuclear-encoded mitochondrial ATPase [7].
Studies in knockout (Spg7/) mice revealed that loss of
SPG7 triggers ATPase deficiency and mitochondrial dys-
function [8]. Upon further examination of these mice, it
was clear that the mitochondrial dysfunction was a result
of paraplegin loss, leading to accumulation of abnormal
proteins and impairment of anterograde and retrograde
transport which caused axonal degeneration. Furthermore,
in patient muscle biopsies, similar mitochondrial impair-
ment was observed [9]. Additional studies also report
how paraplegin functions to degrade misfolded proteins
and regulate ribosome assembly [10, 11].
Clinically, patients with the SPG7 subtype may present
with a pure form of HSP and display the aforementioned
symptoms [12]. On the other hand, complex forms also
occur and include additional symptoms such as cortical
and cerebellar atrophy, optic neuropathy, and peripheral
neuropathy. In our case study, we describe a patient with
a compound heterozygous SPG7 variant and previously
unreported symptoms, involving palatal tremor and
macrocephaly.
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Case History
The patient, a 46-year-old man, initially presented at our
clinic with progressive difficulties with gait and balance.
Onset of these symptoms first appeared 5 years prior and
evolved to include changes in speech, frequent choking
while eating and increased occurrence of falls. The patient
did not report similar findings in additional family mem-
bers and remarked that as a child he suffered from speech
delay but took normal classes during high school.
Recently, his wife explained that she noticed a gradual
decrease in cognition, revealing that his full-scale IQ has
dropped from 115 to 85 over the last 20 years. Due to his
cognitive decline, he was unable to keep employment at
his job of 20 years.
Neurological investigations
A comprehensive neurological examination revealed
several salient findings, including mild primarily ataxic
dysarthria, palatal tremor, and ataxic saccades. In a
visual fixation test, microsquare wave jerks were also evi-
dent. Tandem-walking was impaired. The patient’s casual
gait revealed an erect posture with a normal arm swing;
however, his base was wide and bilateral circumduction
was present. Postural reflexes were impaired on pull test-
ing, and Romberg’s sign was absent. While standing,
there were no subjective or palpable lower extremity
movements. Appendicular ataxia was present, including
dysdiadochokinesia and moderate dyssynergia on heel-
skin testing. No limb weakness was observed, although
the patient had pathologically brisk myotatic stretch
reflexes at the knees. His head circumference measured
above the 97th percentile at 63.5 cm diagnostic of
macrocephaly, and a recent brain MRI revealed only
mild cerebellar atrophy. Specifically, the white matter
was normal.
Genetic Testing
Prior to visiting our clinic, the patient was tested for dis-
ease-causing genetic variants using a comprehensive ataxia
panel test from Athena diagnostics. Sequencing results
were negative for pathogenic disease-causing variants in
all gene screened in this panel (i.e., ADCK3, AFG3L2,
ANO10, APTX, ATM, ATN1, ATXN1, ATXN10, ATXN2,
ATXN3, ATXN7, ATXN8OS, CACNA1A, CACNB4, EEF2,
FGF14, FLVCR1, FXN, GRM1, ITPR1, KCNA1, KCNC3,
KCND3, MRE11A, MTPAP, PDYN, POLG, PPP2R2B,
PRKCG, SACS, SETX, SIL1, SLC1A3, SPTBN2, SYNE1,
SYT14, TBP, TDP1, TGM6, TTBK2, TTPA, VAMP1). To
further examine this patient for any underlying genetic
disorders, we submitted samples from the patient, his
mother, and his father for whole exome sequencing at
GeneDx. Using genomic DNA, exonic regions and flank-
ing splice junctions were sequenced and aligned to refer-
ence sequences on the human genome using standard
methods. Results revealed compound heterozygous vari-
ants in SPG7 involving a p.Ala510Val (c.1529C>T) patho-
genic variant and a p.Arg485_Glu487del (c.1454_1462del)
variant. The c.1529C>T variant inherited from his mother
is a common pathogenic variant identified in patients
with autosomal recessive SPG7. Our patient also inherited
a different SPG7 variant, c.1454_1462del, from his father.
The presence of these bi-allelic pathogenic variants is con-
sistent with a diagnosis of SPG7, a rare neurodegenerative
disorder depicted by his presenting symptoms.
Discussion
Spastic paraplegia type 7 onset typically occurs in adult-
hood, but certain cases have been reported as early as 11-
year old and late as 72-year old [13]. The majority of
SPG7 affected individuals have proximal or widespread
weakness in their legs in addition to various other symp-
toms (e.g., ataxia, intellectual disability, optic nerve atro-
phy, and cervical dystonia) [2]. Furthermore, when
comparing previous studies and our own case, there is no
correlation between a specific genotype and a patient’s
phenotype. The variants our patient acquired have previ-
ously been described as causing both pure and complex
HSP [3]. Moreover, we are the first to report macro-
cephaly and palatal tremor in a patient with SPG7, which
represents an expansion of the clinical phenotype for this
disorder. Due to his presentation, Alexander’s disease was
a strong consideration: However, the patient was not
found to have a pathogenic variant in glial fibrillary acidic
protein (GFAP) [14, 15]. Interestingly, ataxias and spastic
paraplegias are part of a disease continuum and often
have overlapping phenotypes and genetic causes. In fact,
pathogenic variants in SPG7, SYNE1, and PNPLA6 are
known to cause both inherited ataxias and HSP [16].
Panel testing for hereditary ataxias was uninformative in
our case, making whole exome sequencing essential for
the correct diagnosis. Knowing this, future ataxia or HSP
panels should be designed to include genes that are
involved in both diseases.
At this time, there is no treatment for SPG7. Our
patient is currently being treated for sleep apnea with
Continuous Positive Airway Pressure therapy and will be
monitored for any remarkable changes due to his SPG7.
In conclusion, our case report emphasizes the importance
of genetic testing when diagnosing rare neurodegenerative
disorders and expands the phenotypic spectrum of SPG7.
Along with Alexander’s disease, SPG7 should be consid-
ered in the setting of PAPT.
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